An interventional study of Quran recital in Multiple Sclerosis, sponsored by Artvin Coruh University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-22.
Sponsored by Artvin Coruh University · Not applicable, Interventional, and Supportive care
This study will be conducted to evaluate the effects of Quran recital on fatigue and mental well-being in patients with multiple sclerosis.
Hypotheses:
50 patients who meet the inclusion criteria and voluntarily agree to participate in the study will be determined. These patients will be informed about the study and their consent will be obtained. These patients will then be randomized into the Quran recital group and the control group. Personal and contact information of the patients will be recorded and pre-test forms will be applied. The Quran recital group will be asked to listen to the Quran for half an hour with an mp3 player given to them 3 days a week (Monday-Wednesday-Friday) between 21:00-22:00 and this practice will be continued for 4 weeks. The patients will be called by the researcher to ask whether they continue this practice. The control group will continue their routine treatment and care and no additional intervention will be applied. The final test measurements will be made by meeting with the patients in the hospital at the end of the 4th week.
3,264 studies on the registry are indexed under Multiple Sclerosis; 659 are open to participants now.
This study's planned enrollment of 52 is close to the median of 50 across 2,201 interventional studies indexed under Multiple Sclerosis.
Browse Multiple Sclerosis studies →Artvin Coruh University is the lead sponsor of 29 studies on the registry; 16 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The Quran recital group will be asked to listen to the Quran (Surah Yasin) for half an hour with an mp3 player given to them between 21:00-22:00 3 days a week (Monday-Wednesday-Friday) and they will be asked to continue this practice for 4 weeks. The patients will be called by the researcher to ask whether they continue this practice. The final test measurements will be made at the end of the 4th week by interviewing the patients at the hospital.
Behavioral: Quran recital
Personal and contact information about the patients will be recorded and pre-test forms will be applied. The control group will continue their routine treatment and care and no additional intervention will be applied. Post-test measurements will be made by meeting with the patients at the hospital at the end of the 4th week.
The Quran recital group will be asked to listen to the Quran (Surah Yasin) for half an hour with an mp3 player given to them between 21.00-22.00 three days a week (Monday-Wednesday-Friday) and they will be asked to continue this practice for 4 weeks.
Fatigue Impact
The Fatigue Impact Scale (FIS)
Time frame: 1 mount
Fatigue Severity Warwick-Edinburgh Mental Well-Being Scale
The Fatigue Severity Scale (FSS)
Time frame: 1 mount
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for May 2026, 8 months after the start.
Of 847 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 43. This study's planned 8 months is below that.
Counting every sponsor, half of 869 studies reached it within 21 months; a quarter within 9 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Artvin Coruh University